Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
52.26%
Operating Margin
0.35%
Net Margin
-18.26%
Efficiency Metrics
Revenue per Expense Ratio
1.03
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
44.50%
Income Tax Rate
679,600,000.0%
EPS
-1.3600000000
Balance Sheet Analysis
Current Ratio
0.95
Cash Ratio
0.25
Working Capital
$-18.50M
Debt to Equity
1.43
Debt to Assets
53.13%
Equity Ratio
37.16%
Cash Flow Analysis
Operating Cash Flow Ratio
24.39%
Free Cash Flow Ratio
23.79%
CapEx to Revenue
0.60%
Dividends Paid
$75.76M
Stock Buybacks
$1.37M
Total Shareholder Returns
$77.13M
Cash Position Change
-58.30%
Key Takeaways (2023 FY)
Revenue declined by 7.2037878669764%, indicating potential market challenges
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-7.20%
Net Income
-4.49%
EPS
-17.24%
Operating Income
-98.13%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-5.71%
Operating Cash Flow
-37.14%
Free Cash Flow
-10.41%
Balance Sheet Health
Assets
-11.13%
Debt
-19.06%
Book Value per Share
-6.54%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-54.22%
Shares Outstanding
-1.93%
Long Term Trends
3Y Revenue/Share
28.52%
5Y Revenue/Share
44.18%
3Y Dividend/Share
-46.49%
5Y Dividend/Share
-46.54%